HPTN 077 logo where the 0 in 077 is a circular life preserver

A Phase IIa Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the Investigational Injectable HIV Integrase Inhibitor, GSK1265744, in HIV-uninfected Men and Women

OBJECTIVE

This study evaluated the safety, tolerability, and pharmacokinetics (which is how the body interacts with drugs) of an investigational, injectable HIV medicine (GSK1265744) in healthy, HIV-uninfected adults.

STUDY TYPE: HIV Prevention

DURATION: February 2015 - July 2018

PHASE: IIA

STUDY DESIGN: Randomized, parallel assigned, quadrupal masked interventional study

POPULATION: Healthy volunteers aged 18 - 65 years old

NUMBER OF SITES: 8

SITE LOCATIONS: US, Brazil, Malawi, and South Africa

STATUS: Complete

RESULTS